Floatz logo

Sacituzumab Tirumotecan

Programmed Cell Death-1 (PD1, PD-1)

Merck Sharp & Dohme LLCantibody_drug_conjugatePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Programmed Cell Death-1 (PD1, PD-1) cohort.

Asset / SponsorPhaseRating
Tuvonralimab
Hebei Medical University Fourth Hospital
Phase 4BB
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1CC

Same molecule, other indications

Sacituzumab Tirumotecan is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →